<--- Back to Details
First PageDocument Content
Pharmacology / Merck / Rofecoxib / Sulfones / Pfizer / The New England Journal of Medicine / Pharmaceutical industry / Celecoxib / Food and Drug Administration / COX-2 inhibitors / Pharmaceutical sciences / Chemistry
Date: 2009-11-16 16:09:56
Pharmacology
Merck
Rofecoxib
Sulfones
Pfizer
The New England Journal of Medicine
Pharmaceutical industry
Celecoxib
Food and Drug Administration
COX-2 inhibitors
Pharmaceutical sciences
Chemistry

Prospect October:Prospect March

Add to Reading List

Source URL: www.jimgiles.net

Download Document from Source Website

File Size: 131,36 KB

Share Document on Facebook

Similar Documents

Superior drug derivatives via late stage hydroxylation Microsomal and microbial biotransformation of drugs There is increasing focus on thorough investigation of drug metabolites, exemplified by Pfizer’s routine biocat

DocID: 1v0tF - View Document

Plasma Protein Binding: Friend or Foe in Drug Discovery? Kevin Beaumont and Tristan Maurer Pharmacokinetics, Dynamics and Metabolism Pfizer Worldwide Research and Development Memorial Drive, Cambridge

DocID: 1uQg4 - View Document

Dárci 2010 Finanční dary SAZKA Praha ROCHE Praha Pfizer s.r.o. Praha Novartis s.r.o., Praha

DocID: 1tU5V - View Document

Clonazepam 2 mg costo. Getting to know Microsoft Money for Lconazepam Clonazepam 2 mg costo takes only pfizer terramycin la few minutes, and its time well spent. Hutton CThe Meteorology And Climate Of Tropical A

DocID: 1tffN - View Document

JP Morgan Healthcare Conference Advancing Differentiated High Value Products Mikael Dolsten, M.D., Ph.D. President Worldwide R&D January 13, 2015

DocID: 1t2Pn - View Document